Leonardo de Freitas Ferreira

Leonardo de Freitas Ferreira

Auto-generated profile, based on publicly available information

Leonardo de Freitas Ferreira

Universidade Federal da Paraíba

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Pesquisa Brasileira em Odontopediatria e Clínica Integrada
Verified
Journal Article
Open access
PDF file
YCYuri Cavalcanti
Yuri Cavalcanti
RSRennis Oliveira da Silva
Rennis Oliveira da Silva
LFLeonardo de Freitas Ferreira
Leonardo de Freitas Ferreira
ELEdson Hilan Gomes de Lucena
Edson Hilan Gomes de Lucena
ASAndreza Maria Luzia Baldo de Souza
Andreza Maria Luzia Baldo de Souza
APAntonio Carlos Pereira
Antonio Carlos Pereira
COVID-19 pandemic implied new biosafety recommendations to avoid dissemination of SARS-CoV-2 virus within healthcare centers. Changes on recommended personal protective equipment (PPE), decontamination protocols and organization of patient demand resulted may result in cost variation. Based on this, the present study aimed to evaluate the economic impact of new biosafety recommendations for oral healthcare assistance during COVID-19. An Activity Based Costing evaluation was used to calculate the acquisition of PPE and decontamination solutions recommended for dental practice during COVID-19 pandemic in Brazil. PPE and decontamination solutions quantity and frequency of use were based on the newly COVID-19 recommendations. Costs (in Brazilian Real - R$) for biosafety recommendations pre- and post-COVID-19 were outlined and calculated for each patient, service shift and year. A sensitivity analysis considered 20% variation of direct costs. Previously to COVID-19 pandemic, direct costs of biosafety recommendations consisted of R$0.84 per patient, R$6.69 per service shift and R$3,413.94 per year. Post-COVID-19 costs of biosafety recommendations resulted in R$16.01 per patient, R$128.07 per service shift, and R$32,657.96 per year. Yearly costs can vary between R$26,126.37 and R$39,189.56. The annual budget increase necessary to adopt post-COVID biosafety recommendations was R$29,244.02. Newly biosafety recommendations increased significantly the costs of oral healthcare assistance during COVID-19 pandemic. Decision making of healthcare managers must consider rational and equity allocation of financial resources.

19 June 2020 in SciELO Preprints
Verified
Preprint
Open access
YCYuri Cavalcanti
Yuri Cavalcanti
RSRennis Oliveira da Silva
Rennis Oliveira da Silva
LFLeonardo de Freitas Ferreira
Leonardo de Freitas Ferreira
ELEdson Hilan Gomes Lucena
Edson Hilan Gomes Lucena
ASAndreza Maria Luzia Baldo de Souza
Andreza Maria Luzia Baldo de Souza
APAntonio Carlos Pereira
Antonio Carlos Pereira
COVID-19 pandemic implied new biosafety recommendations to avoid dissemination of SARS-CoV-2 virus within healthcare centers. Changes on recommended personal protective equipment (PPE), decontamination protocols and organization of patient demand resulted may result in cost variation. Based on this, the present study aimed to evaluate the economic impact of new biosafety recommendations for oral healthcare assistance during COVID-19. An Activity Based Costing evaluation was used to calculate the acquisition of PPE and decontamination solutions recommended for dental practice during COVID-19 pandemic in Brazil. PPE and decontamination solutions quantity and frequency of use were based on the newly COVID-19 recommendations. Costs (in Brazilian Real – R$) for biosafety recommendations pre- and post-COVID-19 were outlined and calculated for each patient, service shift and year. A sensitivity analysis considered 20% to 50% variation of direct costs. Previously to COVID-19 pandemic, direct costs of biosafety recommendations consisted of R$0.84 per patient, R$6.69 per service shift and R$3,413.94 per year. Post-COVID-19 costs of biosafety recommendations resulted in R$16.01 per patient, R$128.07 per service shift, and R$32,657.96 per year. Yearly costs can vary between R$26,126.37 and R$39,189.56. The annual budget increase necessary to adopt post-COVID biosafety recommendations was R$29,244.02. Newly biosafety recommendations increased significantly the costs of oral healthcare assistance during COVID-19 pandemic. Decision making of healthcare managers must consider rational and equity allocation of financial resources.

28 March 2021 in Research, Society and Development
Verified
Journal Article
Open access
PDF file
MCMoan Jefter Fernandes Costa
Moan Jefter Fernandes Costa
AMAlice Castro Guedes Mendonça
Alice Castro Guedes Mendonça
LFLeonardo de Freitas Ferreira
Leonardo de Freitas Ferreira
HDHugo Victor Dantas
Hugo Victor Dantas
BVBasilio Rodrigues Vieira
Basilio Rodrigues Vieira
EDEugenia Livia de Andrade Dantas
Eugenia Livia de Andrade Dantas
A microtomografia computadorizada utiliza o princípio de raios-x para formação de imagens bi e tridimensionais de amostras pequenas com alta resolução. O encontro anual da Sociedade Brasileira de Pesquisa Odontológica (SBPqO) é o maior evento de produção científica em Odontologia do país. O perfil dos trabalhos expostos pode identificar características da pesquisa científica produzida nacionalmente. O objetivo deste estudo foi analisar retrospectivamente a produção científica envolvendo microtomografia computadorizada (Micro-CT) nos suplementos das reuniões do SBPqO de 2009 a 2018. Após leitura dos anais de todos os anos utilizando os descritores “Microtomografia Computadorizada”, “Micro-CT”, “MicroCT”, “mCT”, “mTC” e “µCT”, a amostra final foi um total de 348 estudos utilizando Micro-CT. O ano com maior número de resumos foi 2016 (22,7%; n=79). Os estudos foram mais frequentes na região Sudeste (86,2%; n=300), com mais estudos na área de endodontia (35,0%; n=122), sendo os elementos dentários humanos mais utilizados como amostras (53,7%; n=187). Houve aumento no número de pesquisas envolvendo Micro-CT, mas houve maior concentração para a região Sudeste e para a área de endodontia. Assim, destaca-se a necessidade de disseminação do conhecimento para que outras áreas também possam utilizar essa ferramenta e aumentar o escopo da produção odontológica.

1 January 2024 in Brazilian Journal Of Pain
Verified
Journal Article
Open access
PDF file
LFLeonardo de Freitas Ferreira
Leonardo de Freitas Ferreira
RSRênnis Oliveira da Silva
Rênnis Oliveira da Silva
ELEdson Hilan Gomes de Lucena
Edson Hilan Gomes de Lucena
YCYuri Cavalcanti
Yuri Cavalcanti
BACKGROUND AND OBJECTIVES: The extraction of third molars can lead to undesired effects such as pain, trismus, and edema, necessitating preemptive therapy to alleviate these effects. For this purpose, an economic evaluation was conducted to analyze the cost-effectiveness of preemptive drugs used in the extraction of third molars. METHODS: Costs were obtained from a market survey. Effectiveness measures were limitation of interincisal distance and postoperative pain, obtained from randomized clinical trials in the literature. For both models, a Monte Carlo simulation generated a hypothetical cohort of a thousand individuals, considering a 5% variation in estimates. The evaluated therapies were dexamethasone 8 mg (DX8); methylprednisolone 40 mg (MP); diclofenac 50 mg associated with tramadol 50 mg (DCTR); and dexamethasone 4mg associated with tramadol 50 mg (DXTR). RESULTS: MP and DCTR therapies were dominated in all scenarios. For the reduction of postoperative pain, DXTR treatment showed the best cost-benefit, with a net monetary benefit (NMB) gain of 31.10% compared to the lowest-cost treatment (DX, R$ 1.76). Considering the reduction in limitation of interincisal distance, DXTR medication presented higher cost-benefit compared to DX8 (NMB gain = 18.25%), being a preferred option alongside DX8. CONCLUSION: In the extraction of third molars, preemptive administration of dexamethasone 4mg associated with tramadol 50mg is the preferred cost-effective option to reduce postoperative pain and limitation of interincisal distance after 48 hours.

1 January 2024 in Brazilian Journal Of Pain
Verified
Journal Article
Open access
PDF file
LFLeonardo de Freitas Ferreira
Leonardo de Freitas Ferreira
RSRênnis Oliveira da Silva
Rênnis Oliveira da Silva
ELEdson Hilan Gomes de Lucena
Edson Hilan Gomes de Lucena
YCYuri Cavalcanti
Yuri Cavalcanti
BACKGROUND AND OBJECTIVES: The extraction of third molars can lead to undesired effects such as pain, trismus, and edema, necessitating preemptive therapy to alleviate these effects. For this purpose, an economic evaluation was conducted to analyze the cost-effectiveness of preemptive drugs used in the extraction of third molars. METHODS: Costs were obtained from a market survey. Effectiveness measures were limitation of interincisal distance and postoperative pain, obtained from randomized clinical trials in the literature. For both models, a Monte Carlo simulation generated a hypothetical cohort of a thousand individuals, considering a 5% variation in estimates. The evaluated therapies were dexamethasone 8 mg (DX8); methylprednisolone 40 mg (MP); diclofenac 50 mg associated with tramadol 50 mg (DCTR); and dexamethasone 4mg associated with tramadol 50 mg (DXTR). RESULTS: MP and DCTR therapies were dominated in all scenarios. For the reduction of postoperative pain, DXTR treatment showed the best cost-benefit, with a net monetary benefit (NMB) gain of 31.10% compared to the lowest-cost treatment (DX, R$ 1.76). Considering the reduction in limitation of interincisal distance, DXTR medication presented higher cost-benefit compared to DX8 (NMB gain = 18.25%), being a preferred option alongside DX8. CONCLUSION: In the extraction of third molars, preemptive administration of dexamethasone 4mg associated with tramadol 50mg is the preferred cost-effective option to reduce postoperative pain and limitation of interincisal distance after 48 hours.